Galaxy: The top seven deals accounted for nearly half of Q3 investment activity, suggesting the golden age of pre-seed round investing may be over.
Galaxy Digital research report pointed out that in the third quarter of this year, seven large transactions raised more than $2.26 billion, accounting for 48.7% of the total venture capital investment in cryptocurrency and blockchain-related companies during the same period.
During this period, venture capital firms invested $4.65 billion in 415 transactions in startups and private companies focused on cryptocurrency, a quarter-on-quarter increase of 290%, but still below the levels of 2021-2022. The growth was mainly driven by late-stage companies, indicating that capital continues to concentrate on mature companies rather than early-stage startups.
Although market sentiment is improving and investment activity is increasing, Galaxy Digital believes that "the golden age of pre-seed cryptocurrency venture capital has passed."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Earnings Preview | After a 30% Drop in Stock Price, Will HBM4 Mass Production and DRAM Price Increases Reignite SK Hynix (SKHY.US) Rally?
SK Hynix will announce its financial results for the third quarter of fiscal year 2026 on October 28.
Cyclical stocks always peak when they're “cheapest” — Citrini, the “chip influencer” who was the earliest to be bullish on AI hardware, is now quietly exiting
Citrini, once the most prominent bull in AI hardware, has now significantly reduced his semiconductor holdings and currently holds some short positions. He believes that the financing structure for AI infrastructure has shifted from tech giants' own cash flows to equity and debt markets, and that sentiment alone could sever the funding chain and impact fundamentals. Strategically, he is long Meta and short Google. Citrini also asserts that the bottleneck in AI pharmaceutical development is not computational power, but rather a "lack of monkeys."
New Zealand Dollar gains ground to near 0.5700 as RBNZ rate hike bets rise
Median survival prolonged by 5.7 months! Roche (RHHBY.US) lung cancer new drug wins in head-to-head trial, major catalyst for oncology business
Roche's investigational lung cancer drug divarasib extended patient survival by nearly six months compared to competing therapies in a late-stage clinical trial, promising to further strengthen the Swiss pharmaceutical company's oncology portfolio.
Crypto prices
More
